Key Takeaways
- • Integer completed its $5.7 billion sale to an affiliate of investment funds managed by KKR, with the Texas-based CDMO's common stock ceasing trading and delisting from the New York Stock Exchange.
- • Integer shareholders will receive $127 per share in cash under the transaction, which was announced in August 2026 and approved by shareholders in October 2026.
- • Integer, one of the world's largest medical device CDMOs serving cardiovascular, neuromodulation, and cardiac rhythm management markets, ranks as the 56th-largest medical device company globally per the 2026 Medical Design & Outsourcing Medtech Big 100.
- • KKR partner Max Lin said KKR sees significant opportunities to leverage its resources to support Integer's next phase of growth and expand its capabilities.
- • The deal is the latest in a 2026 wave of private equity acquisitions of medical device contract manufacturers, as sponsors pursue profit opportunities in medtech CDMOs and larger OEMs.
Summary
Integer, a Texas-based contract development and manufacturing organization, serves the cardiovascular, neuromodulation, and cardiac rhythm management markets and is described as one of the world's largest medical device CDMOs. Medical Design & Outsourcing ranks the company as the 56th-largest medical device company in the world in its 2026 Medtech Big 100.
Integer President and CEO Payman Khales said the company has built a reputation as a trusted partner to leading medical device companies and emerging innovators, based on quality, customer service, and innovation. He said that under KKR, the company is well positioned to accelerate its growth strategy and further invest in its people, capabilities, and technologies.
KKR partner Max Lin said the firm was pleased to welcome Integer to the KKR portfolio and looks forward to building on the company's foundation alongside Khales and the management team. Lin said KKR sees significant opportunities to leverage its resources and expertise to support Integer's next phase of growth and strengthen its position in the global medical device industry.
The article notes that Integer is the latest medical device contract manufacturer acquired by private equity firms this year, as sponsors seek profit in the medical device market through CDMOs and larger OEMs.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.